GETI-B Stock Analysis: Getinge ser. | ST
Medical Devices | ST, Sweden | Market Cap: 69.182m SEK | 12M Return: 23.5% | SE0000202624 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 138M
EPS Trend: 80.5%
Qual. Beats: 1
Rev. Trend: 76.3%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Getinge AB (publ) is a Swedish medical technology group founded in 1904 and headquartered in Gothenburg, classified within the Health Care Equipment sub-industry. The company supplies products and solutions for operating rooms, intensive-care units, and sterilization departments to hospital and life-science customers in Sweden and internationally.
Operations are organized into three segments. Acute Care Therapies covers extracorporeal membrane oxygenation (ECMO), mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. Surgical Workflows provides operating-room equipment, anesthesia, patient monitoring, OR integration, surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation,
- Post-COVID ventilator demand normalization pressures Acute Care revenue
- Biopharma sterilization demand drives Life Science segment growth
- US hospital capital spending slowdown weighs on Surgical Workflows orders
| Net Income: 2.68b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.83 > 1.0 |
| NWC/Revenue: 10.91% < 20% (prev 8.11%; Δ 2.80% < -1%) |
| CFO/TA 0.09 > 3% & CFO 5.03b > Net Income 2.68b |
| Net Debt (10.7b) to EBITDA (6.57b): 1.62 < 3 |
| Current Ratio: 1.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (272.4m) vs 12m ago 0.0% < -2% |
| Gross Margin: 47.57% > 18% (prev 46.89%; Δ 0.68% > 0.5%) |
| Asset Turnover: 60.20% > 50% (prev 62.97%; Δ -2.77% > 0%) |
| Interest Coverage Ratio: 7.41 > 6 (EBIT TTM 4.41b / Interest Expense TTM 595.0m) |
| A: 0.07 (Total Current Assets 15.8b - Total Current Liabilities 12.0b) / Total Assets 57.4b |
| B: 0.37 (Retained Earnings 21.5b / Total Assets 57.4b) |
| C: 0.08 (EBIT TTM 4.41b / Avg Total Assets 56.9b) |
| D: 1.17 (Book Value of Equity 30.9b / Total Liabilities 26.4b) |
| Altman-Z'' = 3.40 = A |
| DSRI: 1.02 (Receivables 6.88b/7.00b, Revenue 34.2b/35.5b) |
| GMI: 0.99 (GM 46.89% / 47.57%) |
| AQI: 1.01 (AQ_t 0.64 / AQ_t-1 0.63) |
| SGI: 0.96 (Revenue 34.2b / 35.5b) |
| TATA: -0.04 (NI 2.68b - CFO 5.03b) / TA 57.4b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at SEK 253.20 with a total of 527,349 shares traded. Over the past week, the price has changed by +2.76%, over one month by +6.34%, over three months by +24.55% and over the past year by +23.47%.
Current recommended Stop Loss: 247.60 (which is 2.2% or 1.2 ATR below the current price).
Getinge ser. has no consensus analysts rating.
P/E Trailing = 25.8393
P/E Forward = 18.0832
P/S = 2.0207
P/B = 2.1635
P/EG = 1.3299
Revenue TTM = 34.2b SEK
EBIT TTM = 4.41b SEK
EBITDA TTM = 6.57b SEK
Long Term Debt = 7.94b SEK (from longTermDebt, last quarter)
Short Term Debt = 2.01b SEK (from shortTermDebt, last quarter)
Debt = 12.7b SEK (from shortLongTermDebtTotal, last quarter) + Leases 1.62b
Net Debt = 10.7b SEK (calculated: Debt 12.7b - CCE 2.05b)
Enterprise Value = 79.9b SEK (69.2b + Debt 12.7b - CCE 2.05b)
Interest Coverage Ratio = 7.41 (Ebit TTM 4.41b / Interest Expense TTM 595.0m)
EV/FCF = 20.99x (Enterprise Value 79.9b / FCF TTM 3.80b)
FCF Yield = 4.76% (FCF TTM 3.80b / Enterprise Value 79.9b)
FCF Margin = 11.11% (FCF TTM 3.80b / Revenue TTM 34.2b)
Net Margin = 7.82% (Net Income TTM 2.68b / Revenue TTM 34.2b)
Gross Margin = 47.57% ((Revenue TTM 34.2b - Cost of Revenue TTM 17.9b) / Revenue TTM)
Gross Margin QoQ = 52.69% (prev 48.45%)
Tobins Q-Ratio = 1.39 (Enterprise Value 79.9b / Total Assets 57.4b)
Interest Expense / Debt = 4.68% (Interest Expense 595.0m / Debt 12.7b)
Taxrate = 27.80% (1.03b / 3.72b)
NOPAT = 3.18b (EBIT 4.41b * (1 - 27.80%))
Current Ratio = 1.31 (Total Current Assets 15.8b / Total Current Liabilities 12.0b)
Debt / Equity = 0.41 (Debt 12.7b / totalStockholderEquity, last quarter 30.9b)
Debt / EBITDA = 1.62 (Net Debt 10.7b / EBITDA 6.57b)
Debt / FCF = 2.81 (Net Debt 10.7b / FCF TTM 3.80b)
Total Stockholder Equity = 30.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.71% (Net Income 2.68b / Total Assets 57.4b)
RoE = 8.88% (Net Income TTM 2.68b / Total Stockholder Equity 30.1b)
RoCE = 11.59% (EBIT 4.41b / Capital Employed (Equity 30.1b + L.T.Debt 7.94b))
RoIC = 6.98% (NOPAT 3.18b / Invested Capital 45.6b)
WACC = 6.63% (E(69.2b)/V(81.9b) * Re(7.23%) + D(12.7b)/V(81.9b) * Rd(4.68%) * (1-Tc(0.28)))
Discount Rate = 7.23% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 63.96 | Cagr: 0.00%
[DCF] Terminal Value 77.97% ; FCFF base≈3.36b ; Y1≈3.86b ; Y5≈5.68b
[DCF] Fair Price = 294.1 (EV 85.4b - Net Debt 10.7b = Equity 74.7b / Shares 254.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 80.47 | EPS CAGR: 11.61% | SUE: 2.43 | # QB: 1
Revenue Correlation: 76.28 | Revenue CAGR: 4.36% | SUE: 0.11 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.56 | Chg30d=-3.00% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=12.87 | Chg30d=-0.04% | Revisions=+12% | GrowthEPS=+14.0% | GrowthRev=+1.1%
EPS next Year (2027-12-31): EPS=14.20 | Chg30d=+1.13% | Revisions=+38% | GrowthEPS=+10.4% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: +21% (up=7, down=4)